Yifeng Pharmacy (603939.SS) stock: key figures, P/E, revenue and dividend
Consumer Staples · Drug Retail · China · ISIN CNE100001TS5
Yifeng Pharmacy financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 24.06 bn CNY | 24.43 bn CNY |
| Gross profit | 9.57 bn CNY | 9.62 bn CNY |
| Operating income | 2.20 bn CNY | 2.51 bn CNY |
| EBIT | 2.22 bn CNY | 2.62 bn CNY |
| Net income | 1.53 bn CNY | 1.68 bn CNY |
| Diluted EPS – continuing operations | 1.24 CNY | 1.38 CNY |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Yifeng Pharmacy
Yifeng Pharmacy Chain Co., Ltd. engages in the retail business of pharmaceutical products in China. The company operates through Retail business and Wholesale business segments. The company offers Western and Chinese patent medicine, traditional Chinese medicine herbal pieces, medical devices and equipment, health supplements and products, personal care products, drugs, and convenience products related to health. It is also involved in chronic disease management, medical project investment, and medical technology development, as well as operates internet hospitals and clinics. The company also offers its products through franchise distribution and e-commerce. Yifeng Pharmacy Chain Co., Ltd. was founded in 2001 and is headquartered in Changsha, China.
More stocks
- Grupo Aeroportuario del Centro Norte S.A.B. de C.V (OMAB.MX)
- Berner Kantonalbank AG (BEKN.SW)
- Beijing Enterprises Holdings Ltd (392.HK)
- Hirose Electric Co Ltd (6806.T)
- HA Sustainable Infrastructure Capital, Inc. (HASI)
- Nippon Television Holdings Inc (9404.T)
- CREDIT ACCEPTANCE CORP (CACC)
- Erasca, Inc. (ERAS)
- Hangzhou Great Star Industrial Co Ltd (002444.SZ)
- COUSINS PROPERTIES INC (CUZ)
- Applied Digital Corp. (APLD)
- China Resources Gas Group Ltd (1193.HK)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.